Pharma fun: The Tipline for 26 February 2019

It is a busy week for antitrust in the pharmaceutical industry. In today’s Tipline, we have coverage of the Federal Trade Commission’s loss in an appeal against Shire ViroPharma and a drugmaker trying to get out of the states’ generic antitrust litigation. On the distribution side, the Department of Justice is seeking final approval for its settlement in the CVS/Aetna merger. GCR USA heads to Capitol Hill today, where the Senate Committee on Finance will question pharmaceutical executives from AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Merck, Pfizer and Sanofi. All this has us well-prepared for the inaugural GCR Live Pharmaceuticals event on Thursday.

Get unlimited access to all Global Competition Review content